skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach

Abstract

Granulomas are complex lung lesions that are the hallmark of tuberculosis (TB). Understanding antibiotic dynamics within lung granulomas will be vital to improving and shortening the long course of TB treatment. Three fluoroquinolones (FQs) are commonly prescribed as part of multi-drug resistant TB therapy: moxifloxacin (MXF), levofloxacin (LVX) or gatifloxacin (GFX). To date, insufficient data are available to support selection of one FQ over another, or to show that these drugs are clinically equivalent. To predict the efficacy of MXF, LVX and GFX at a single granuloma level, we integrate computational modeling with experimental datasets into a single mechanistic framework, GranSim. GranSim is a hybrid agent-based computational model that simulates granuloma formation and function, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and in vivo data. We treat in silico granulomas with recommended daily doses of each FQ and compare efficacy by multiple metrics: bacterial load, sterilization rates, early bactericidal activity and efficacy under non-compliance and treatment interruption. GranSim reproduces in vivo plasma pharmacokinetics, spatial and temporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs. We predict that MXF kills intracellular bacteria more quickly than LVX and GFX due in part to amore » higher cellular accumulation ratio. We also show that all three FQs struggle to sterilize non-replicating bacteria residing in caseum. This is due to modest drug concentrations inside caseum and high inhibitory concentrations for this bacterial subpopulation. MXF and LVX have higher granuloma sterilization rates compared to GFX; and MXF performs better in a simulated non-compliance or treatment interruption scenario. We conclude that MXF has a small but potentially clinically significant advantage over LVX, as well as LVX over GFX. We illustrate how a systems pharmacology approach combining experimental and computational methods can guide antibiotic selection for TB.« less

Authors:
ORCiD logo; ; ; ; ; ORCiD logo; ;
Publication Date:
Research Org.:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States). National Energy Research Scientific Computing Center (NERSC); Univ. of California, Oakland, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1375507
Alternate Identifier(s):
OSTI ID: 1544027
Grant/Contract Number:  
AC02-05CH11231
Resource Type:
Published Article
Journal Name:
PLoS Computational Biology (Online)
Additional Journal Information:
Journal Name: PLoS Computational Biology (Online) Journal Volume: 13 Journal Issue: 8; Journal ID: ISSN 1553-7358
Publisher:
Public Library of Science (PLoS)
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 97 MATHEMATICS AND COMPUTING; Biochemistry & Molecular Biology; Mathematical & Computational Biology

Citation Formats

Pienaar, Elsje, Sarathy, Jansy, Prideaux, Brendan, Dietzold, Jillian, Dartois, Véronique, Kirschner, Denise E., Linderman, Jennifer J., and Diamond, ed., Scott L. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. United States: N. p., 2017. Web. doi:10.1371/journal.pcbi.1005650.
Pienaar, Elsje, Sarathy, Jansy, Prideaux, Brendan, Dietzold, Jillian, Dartois, Véronique, Kirschner, Denise E., Linderman, Jennifer J., & Diamond, ed., Scott L. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. United States. doi:10.1371/journal.pcbi.1005650.
Pienaar, Elsje, Sarathy, Jansy, Prideaux, Brendan, Dietzold, Jillian, Dartois, Véronique, Kirschner, Denise E., Linderman, Jennifer J., and Diamond, ed., Scott L. Thu . "Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach". United States. doi:10.1371/journal.pcbi.1005650.
@article{osti_1375507,
title = {Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach},
author = {Pienaar, Elsje and Sarathy, Jansy and Prideaux, Brendan and Dietzold, Jillian and Dartois, Véronique and Kirschner, Denise E. and Linderman, Jennifer J. and Diamond, ed., Scott L.},
abstractNote = {Granulomas are complex lung lesions that are the hallmark of tuberculosis (TB). Understanding antibiotic dynamics within lung granulomas will be vital to improving and shortening the long course of TB treatment. Three fluoroquinolones (FQs) are commonly prescribed as part of multi-drug resistant TB therapy: moxifloxacin (MXF), levofloxacin (LVX) or gatifloxacin (GFX). To date, insufficient data are available to support selection of one FQ over another, or to show that these drugs are clinically equivalent. To predict the efficacy of MXF, LVX and GFX at a single granuloma level, we integrate computational modeling with experimental datasets into a single mechanistic framework, GranSim. GranSim is a hybrid agent-based computational model that simulates granuloma formation and function, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and in vivo data. We treat in silico granulomas with recommended daily doses of each FQ and compare efficacy by multiple metrics: bacterial load, sterilization rates, early bactericidal activity and efficacy under non-compliance and treatment interruption. GranSim reproduces in vivo plasma pharmacokinetics, spatial and temporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs. We predict that MXF kills intracellular bacteria more quickly than LVX and GFX due in part to a higher cellular accumulation ratio. We also show that all three FQs struggle to sterilize non-replicating bacteria residing in caseum. This is due to modest drug concentrations inside caseum and high inhibitory concentrations for this bacterial subpopulation. MXF and LVX have higher granuloma sterilization rates compared to GFX; and MXF performs better in a simulated non-compliance or treatment interruption scenario. We conclude that MXF has a small but potentially clinically significant advantage over LVX, as well as LVX over GFX. We illustrate how a systems pharmacology approach combining experimental and computational methods can guide antibiotic selection for TB.},
doi = {10.1371/journal.pcbi.1005650},
journal = {PLoS Computational Biology (Online)},
number = 8,
volume = 13,
place = {United States},
year = {2017},
month = {8}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: 10.1371/journal.pcbi.1005650

Citation Metrics:
Cited by: 7 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

A methodology for performing global uncertainty and sensitivity analysis in systems biology
journal, September 2008

  • Marino, Simeone; Hogue, Ian B.; Ray, Christian J.
  • Journal of Theoretical Biology, Vol. 254, Issue 1
  • DOI: 10.1016/j.jtbi.2008.04.011

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
journal, April 2009


A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
journal, October 2014

  • Merle, Corinne S.; Fielding, Katherine; Sow, Omou Bah
  • New England Journal of Medicine, Vol. 371, Issue 17
  • DOI: 10.1056/NEJMoa1315817

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
journal, February 2014


Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis
journal, November 2004

  • Nuermberger, Eric L.; Yoshimatsu, Tetsuyuki; Tyagi, Sandeep
  • American Journal of Respiratory and Critical Care Medicine, Vol. 170, Issue 10
  • DOI: 10.1164/rccm.200407-885OC

Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories
journal, February 2012


Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
journal, January 2011

  • Lee, Jinwoo; Lee, Chang-Hoon; Kim, Deog Kyeom
  • The Korean Journal of Internal Medicine, Vol. 26, Issue 2
  • DOI: 10.3904/kjim.2011.26.2.153

Multiscale Computational Modeling Reveals a Critical Role for TNF-α Receptor 1 Dynamics in Tuberculosis Granuloma Formation
journal, February 2011

  • Fallahi-Sichani, Mohammad; El-Kebir, Mohammed; Marino, Simeone
  • The Journal of Immunology, Vol. 186, Issue 6
  • DOI: 10.4049/jimmunol.1003299

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis
journal, December 2014


A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment
journal, February 2015

  • Pienaar, Elsje; Cilfone, Nicholas A.; Lin, Philana Ling
  • Journal of Theoretical Biology, Vol. 367
  • DOI: 10.1016/j.jtbi.2014.11.021

Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens
journal, September 2004


Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis
journal, February 2004

  • Rodriguez, J. C.
  • Journal of Antimicrobial Chemotherapy, Vol. 53, Issue 3
  • DOI: 10.1093/jac/dkh119

Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms
journal, January 2015

  • Wang, Qingjiang; Zhang, Chunxiao; Guo, Jinhui
  • Experimental and Therapeutic Medicine, Vol. 9, Issue 4
  • DOI: 10.3892/etm.2015.2230

Illustration of Sampling-Based Methods for Uncertainty and Sensitivity Analysis
journal, June 2002


In silico evaluation and exploration of antibiotic tuberculosis treatment regimens
journal, November 2015

  • Pienaar, Elsje; Dartois, Véronique; Linderman, Jennifer J.
  • BMC Systems Biology, Vol. 9, Issue 1
  • DOI: 10.1186/s12918-015-0221-8

Tumor Necrosis Factor Blockers Influence Macrophage Responses to Mycobacterium tuberculosis
journal, December 2008

  • Harris, James; Hope, Jayne. C.; Keane, Joseph
  • The Journal of Infectious Diseases, Vol. 198, Issue 12
  • DOI: 10.1086/593174

Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model
journal, August 2005


Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection
journal, March 2009

  • Ray, J. Christian J.; Flynn, JoAnne L.; Kirschner, Denise E.
  • The Journal of Immunology, Vol. 182, Issue 6
  • DOI: 10.4049/jimmunol.0802297

Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
journal, October 2013

  • Koh, Won-Jung; Lee, Seung Heon; Kang, Young Ae
  • American Journal of Respiratory and Critical Care Medicine, Vol. 188, Issue 7
  • DOI: 10.1164/rccm.201303-0604OC

Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques
journal, June 2006

  • Lin, P. L.; Pawar, S.; Myers, A.
  • Infection and Immunity, Vol. 74, Issue 7
  • DOI: 10.1128/IAI.00064-06

Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice
journal, December 2001


Predicting the Outcome of Therapy for Pulmonary Tuberculosis
journal, April 2000

  • Wallis, Robert S.; Perkins, Mark D.; Phillips, Manijeh
  • American Journal of Respiratory and Critical Care Medicine, Vol. 161, Issue 4
  • DOI: 10.1164/ajrccm.161.4.9903087

Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum
journal, January 2012


The early bactericidal activity of anti-tuberculosis drugs: a literature review
journal, August 2008


The anti-tuberculosis agents under development and the challenges ahead
journal, October 2015

  • Kumar, Deepak; Negi, Beena; Rawat, Diwan S.
  • Future Medicinal Chemistry, Vol. 7, Issue 15
  • DOI: 10.4155/fmc.15.128

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
journal, April 2014

  • Zumla, Alimuddin I.; Gillespie, Stephen H.; Hoelscher, Michael
  • The Lancet Infectious Diseases, Vol. 14, Issue 4
  • DOI: 10.1016/S1473-3099(13)70328-1

Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding
journal, October 2008

  • Waters, Nigel J.; Jones, Rachel; Williams, Gareth
  • Journal of Pharmaceutical Sciences, Vol. 97, Issue 10
  • DOI: 10.1002/jps.21317

NF-κB Activation Controls Phagolysosome Fusion-Mediated Killing of Mycobacteria by Macrophages
journal, August 2008

  • Gutierrez, Maximiliano Gabriel; Mishra, Bibhuti B.; Jordao, Luisa
  • The Journal of Immunology, Vol. 181, Issue 4
  • DOI: 10.4049/jimmunol.181.4.2651

Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates
journal, March 2008

  • Via, L. E.; Lin, P. L.; Ray, S. M.
  • Infection and Immunity, Vol. 76, Issue 6
  • DOI: 10.1128/IAI.01515-07

Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study
journal, July 2013


Medication Compliance and Persistence: Terminology and Definitions
journal, January 2008


Exploring the full spectrum of macrophage activation
journal, December 2008

  • Mosser, David M.; Edwards, Justin P.
  • Nature Reviews Immunology, Vol. 8, Issue 12
  • DOI: 10.1038/nri2448

Steady-State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin, and Azithromycin in Older Adults
journal, March 2004


Multidrug evolutionary strategies to reverse antibiotic resistance
journal, December 2015


Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis
journal, July 2006

  • Rosenthal, Ian M.; Williams, Kathy; Tyagi, Sandeep
  • American Journal of Respiratory and Critical Care Medicine, Vol. 174, Issue 1
  • DOI: 10.1164/rccm.200602-280OC

A replication clock for Mycobacterium tuberculosis
journal, February 2009

  • Gill, Wendy P.; Harik, Nada S.; Whiddon, Molly R.
  • Nature Medicine, Vol. 15, Issue 2
  • DOI: 10.1038/nm.1915

The association between sterilizing activity and drug distribution into tuberculosis lesions
journal, September 2015

  • Prideaux, Brendan; Via, Laura E.; Zimmerman, Matthew D.
  • Nature Medicine, Vol. 21, Issue 10
  • DOI: 10.1038/nm.3937

Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model
journal, December 2004

  • Segovia-Juarez, Jose L.; Ganguli, Suman; Kirschner, Denise
  • Journal of Theoretical Biology, Vol. 231, Issue 3
  • DOI: 10.1016/j.jtbi.2004.06.031

Treatment of Tuberculosis
journal, November 2015

  • Horsburgh, C. Robert; Barry, Clifton E.; Lange, Christoph
  • New England Journal of Medicine, Vol. 373, Issue 22
  • DOI: 10.1056/NEJMra1413919

Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
journal, February 2015

  • Lenaerts, Anne; Barry, Clifton E.; Dartois, Véronique
  • Immunological Reviews, Vol. 264, Issue 1
  • DOI: 10.1111/imr.12252

Functional classification of drugs by properties of their pairwise interactions
journal, March 2006

  • Yeh, Pamela; Tschumi, Ariane I.; Kishony, Roy
  • Nature Genetics, Vol. 38, Issue 4
  • DOI: 10.1038/ng1755

Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model
journal, July 2011

  • Cremades, R.; Rodriguez, J. C.; Garcia-Pachon, E.
  • Journal of Antimicrobial Chemotherapy, Vol. 66, Issue 10
  • DOI: 10.1093/jac/dkr281

Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
journal, August 2006

  • Burman, William J.; Goldberg, Stefan; Johnson, John L.
  • American Journal of Respiratory and Critical Care Medicine, Vol. 174, Issue 3
  • DOI: 10.1164/rccm.200603-360OC

Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing
journal, December 2013

  • Lin, Philana Ling; Ford, Christopher B.; Coleman, M. Teresa
  • Nature Medicine, Vol. 20, Issue 1
  • DOI: 10.1038/nm.3412

Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response
journal, December 2011

  • Subbian, Selvakumar; Tsenova, Liana; Yang, Guibin
  • Open Biology, Vol. 1, Issue 4
  • DOI: 10.1098/rsob.110016

Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis
journal, December 2007

  • Peloquin, C. A.; Hadad, D. J.; Molino, L. P. D.
  • Antimicrobial Agents and Chemotherapy, Vol. 52, Issue 3
  • DOI: 10.1128/AAC.01036-07

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
journal, February 2004

  • Nuermberger, Eric L.; Yoshimatsu, Tetsuyuki; Tyagi, Sandeep
  • American Journal of Respiratory and Critical Care Medicine, Vol. 169, Issue 3
  • DOI: 10.1164/rccm.200310-1380OC

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
journal, October 2014

  • Jindani, Amina; Harrison, Thomas S.; Nunn, Andrew J.
  • New England Journal of Medicine, Vol. 371, Issue 17
  • DOI: 10.1056/NEJMoa1314210

Variability in Tuberculosis Granuloma T Cell Responses Exists, but a Balance of Pro- and Anti-inflammatory Cytokines Is Associated with Sterilization
journal, January 2015


Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
journal, October 2014

  • Gillespie, Stephen H.; Crook, Angela M.; McHugh, Timothy D.
  • New England Journal of Medicine, Vol. 371, Issue 17
  • DOI: 10.1056/NEJMoa1407426

Neutrophils Are the Predominant Infected Phagocytic Cells in the Airways of Patients With Active Pulmonary TB
journal, January 2010


Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
journal, March 2011


Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
journal, November 2014

  • Lakshminarayana, Suresh B.; Huat, Tan Bee; Ho, Paul C.
  • Journal of Antimicrobial Chemotherapy, Vol. 70, Issue 3
  • DOI: 10.1093/jac/dku457

Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model
journal, July 2009

  • Lin, P. L.; Rodgers, M.; Smith, L.
  • Infection and Immunity, Vol. 77, Issue 10
  • DOI: 10.1128/IAI.00592-09

Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates
journal, April 2010

  • Saraiva, Maurício F.; de Souza, Marcus V. N.; Tran Huu Dau, Marie E.
  • Carbohydrate Research, Vol. 345, Issue 6
  • DOI: 10.1016/j.carres.2010.01.016

Dry powder inhalable formulations for anti-tubercular therapy
journal, July 2016

  • Parumasivam, Thaigarajan; Chang, Rachel Yoon Kyung; Abdelghany, Sharif
  • Advanced Drug Delivery Reviews, Vol. 102
  • DOI: 10.1016/j.addr.2016.05.011

Computational and Empirical Studies Predict Mycobacterium tuberculosis-Specific T Cells as a Biomarker for Infection Outcome
journal, April 2016


Revisiting the role of the granuloma in tuberculosis
journal, April 2012

  • Ramakrishnan, Lalita
  • Nature Reviews Immunology, Vol. 12, Issue 5
  • DOI: 10.1038/nri3211